If you have a business idea in oncology do check this out, it's a fantastic programme. Applications open now www.cancertechaccelerator.co.uk
04.02.2026 09:00
👍 0
🔁 0
💬 0
📌 0
If you have a business idea in oncology do check this out, it's a fantastic programme. Applications open now www.cancertechaccelerator.co.uk
AlphaMissense promises powerful AI for pathogenic variant identification. Is it clinically useful? Smart validation approach here against known signatures ascopubs.org/doi/10.1200/... Found with researchbriefing.com
Could we “see” intratumoral CD4 cells in vivo with PET? That’s the promise of this novel tracer. Very cool if it works www.science.org/doi/10.1126/... Found with researchbriefing.com
Night shifts increase lung cancer risk - and there's more to it than smoking. Very interesting BioBank analysis here academic.oup.com/sleep/advanc.... Found with researchbriefing.com
Immunotherapy tox is not always bad; can lead to better outcomes. More data on this in the post-CRT NSCLC setting bmcpulmmed.biomedcentral.com/articles/10.... Found with researchbriefing.com
This is a compelling vision of how AI agents will improve our treatment decisions in future www.nature.com/articles/s43.... Impressive progress but still a way from the clinic. Found with researchbriefing.com
I’ve always struggled with dermatology. Never good at identifying skin problems. Now AI can do it for us, and better www.nature.com/articles/s41... - need this in EPIC ASAP! Found with researchbriefing.com
First line ipi nivo for mNSCLC. 19% still responding at 6y. We don’t use this combo but I’m sure there are some patients who would benefit, if we could target them better www.esmoopen.com/article/S205... Found with researchbriefing.com
Cancers are complex. This study shows moving from simple biomarkers to more complex models can improve outcomes www.nature.com/articles/s41... Found with researchbriefing.com
Patients with COPD do better on immunotherapy www.nature.com/articles/s41... Found with researchbriefing.com
In genomics we tend to think in 1D sequences. Great study shows we need think in 3D www.nature.com/articles/s41... Found with researchbriefing.com
How old you look is a better predictor of outcome than how old you are. Another smart AI application shows prognostic value of FaceAge predictor in cancer patients buff.ly/e275kVV Found with researchbriefing.com
Spatial profiling of precancerous lung lesions identifies TIM3 as a potential interception target www.sciencedirect.com/science/arti.... Fantastic study. Found with researchbriefing.com
Can we improve immunotherapy responses by depleting regulatory T-cells? Encouraging data in GBM www.cell.com/immunity/ful... Found with researchbriefing.com
Can we predict patient outcomes by… asking them? Longitudinal analysis of PRO data suggests we can aacrjournals.org/clincancerre... Found with researchbriefing.com
Love this use of AI. Reviewed >600k oncology patient messages to find their main care issues. Great to focus future improvements jamanetwork.com/journals/jam... Found with researchbriefing.com
Clonal haematopoeisis; important in ageing and now associated with worse outcomes when infiltrating tumours. More great work from the TRACERx team www.nejm.org/doi/10.1056/... Found with researchbriefing.com
In scRNAseq how do you find tumour cells? This approach makes sense to me, using CNA profiles inferred from the transcriptome academic.oup.com/bib/article/... Found with researchbriefing.com
Antibiotics can affect immunotherapy efficacy via the microbiome. Should be used with caution. Helpful and detailed guide: ascopubs.org/doi/10.1200/... Found with researchbriefing.com
Adding RT to peri-op chemoIO improves MPR but not OS/PFS www.jto.org/article/S155... Found with researchbriefing.com
MetaGP - medical foundation model improves diagnostic performance of doctors buff.ly/WzRk39a Found with researchbriefing.com
But previous neoadj osimertinib trial declared a failure due to low MPR rate buff.ly/AAyHQO1. Similar MPR rates in both. Good lesson to focus on the endpoint that matters most. Both found with researchbriefing.com
This got me thinking about neoadjuvant trial design. Phase II neoadj EGFR inhibitor declared a success due to high conversion rate to resectability in unresectable stage III disease www.nature.com/articles/s41... (1/2)
Exosomes are definitely interesting for early cancer detection. AI-powered exosome detection using microfluidics seems like a smart approach buff.ly/rKqTrXu Found with researchbriefing.com
Can LLMs design proteins now? Enzymes designed with natural language prompts... incredible... buff.ly/nSvYH9Z Found with researchbriefing.com
People at germline risk of autoimmune diseases also at risk of ICI tox. Makes sense - could lead to better personalisation in future buff.ly/qj0KnOh Found with researchbriefing.com
Could protein translation defects lead to more immunogenic cancers? Could we exploit this vulnerability? Study of key translation proteins suggests so buff.ly/C6PKdF4 Found with researchbriefing.com
Here's a good question - if AI is so good at radiology interpretation, can we reduce the radiation dose? Study suggests you can, and AI copes fine with reduced quality buff.ly/GkzyUN5 Found with researchbriefing.com
DCIS recurrence is not the same as DCIS progression. Fascinating evolutionary study with important implications breast-cancer-research.biomedcentral.com/articles/10.... Found with researchbriefing.com
Serum VEGF-A as a biomarker for bevacizumab? Intriguing data www.nature.com/articles/s41... Found with researchbriefing.com